Effect of Single-Dose and Short-Term Administration of Si Jun Zi Tang on the Pharmacokinetics of Gefitinib in Rats
Open Access
- 26 July 2021
- journal article
- research article
- Published by Hindawi Limited in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-8
- https://doi.org/10.1155/2021/6655449
Abstract
Background. Si Jun Zi Tang (SJZ), a four-herb Chinese medicine formula that has been described for approximately one thousand years, is often prescribed for cancer patients as a complementary therapy in China. However, the mechanism by which Si Jun Zi Tang enhances the efficacy of gefitinib is unclear. Methods. We investigated how Si Jun Zi Tang affected the pharmacokinetics of gefitinib in rats. A rapid, specific, and reliable ultra-performance liquid chromatography method with mass spectrometry was established to determine the plasma concentration of gefitinib. Results. The results showed that a single intragastrically administered dose of Si Jun Zi Tang increased the pharmacokinetic parameters of gefitinib (Cmax, 3156.13μg/L; A UC, 46281.5μg/L/h) by 3 folds in rats compared with the administration of gefitinib alone (Cmax, 1352.07μg/L; AUC, 11823.7μg/L/h). Si Jun Zi Tang could also alter the pharmacokinetics of gefitinib by prolonging the time to reach Cmax. Conclusions. Potential pharmacokinetic interactions between gefitinib and SJZ were evaluated, and SJZ extended Tmax and T1/2 and increased the Cmax and AUC of gefitinib. Long-term administration of gefitinib in combination with Si Jun Zi Tang would improve the efficacy of gefitinib.Keywords
Funding Information
- Chinese Academy of Medical Sciences (2016-I2 M-1-001)
This publication has 17 references indexed in Scilit:
- Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography–tandem mass spectrometry: Application to pharmacokinetic interaction studiesJournal of Pharmaceutical and Biomedical Analysis, 2016
- Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC–MS/MS and its application to a pharmacokinetics studyJournal of Chromatography B, 2016
- Understanding interactions between Chinese medicines and pharmaceutical drugs in integrative healthcareChinese Journal of Integrated Medicine, 2014
- Bioactive components of Glycyrrhiza uralensis mediate drug functions and properties through regulation of CYP450 enzymesMolecular Medicine Reports, 2014
- Herb-drug interaction: An emerging issue of integrative medicineChinese Journal of Integrated Medicine, 2010
- Simultaneous Quantification of Erlotinib, Gefitinib, and Imatinib in Human Plasma by Liquid Chromatography Tandem Mass SpectrometryTherapeutic Drug Monitoring, 2009
- Ginsenoside Metabolites, Rather Than Naturally Occurring Ginsenosides, Lead to Inhibition of Human Cytochrome P450 EnzymesToxicological Sciences, 2006
- Pharmacokinetic Drug Interactions of Gefitinib with Rifampicin, Itraconazole and MetoprololClinical Pharmacokinetics, 2005
- LACK OF EVIDENCE FOR INDUCTION OF CYP2B1, CYP3A23, AND CYP1A2 GENE EXPRESSION BY Panax ginseng AND Panax quinquefolius EXTRACTS IN ADULT RATS AND PRIMARY CULTURES OF RAT HEPATOCYTESDrug Metabolism and Disposition, 2004
- Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activityLife Sciences, 1999